Cocrystal Pharma (COCP) Share-based Compensation (2011 - 2026)
Cocrystal Pharma (COCP) posted Share-based Compensation of $84000.0 for Q1 2026, up 50.0% sequentially from $56000.0 in Q4 2025, and up 2.44% YoY from $82000.0 in Q1 2025.
Cocrystal Pharma (COCP) Share-based Compensation (2011 - 2026) Analysis & Trends
Cocrystal Pharma has reported Share-based Compensation for 14 years, with the latest figure at $84000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 2.44% year-over-year to $84000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $307000.0 (down 47.52% YoY) and the FY2025 annual result came in at $270000.0, down 58.01% from the prior year.
- Share-based Compensation advanced to $84000.0 in Q1 2026 per COCP's latest filing, from $56000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $643000.0 in Q3 2022 and troughed at $56000.0 in Q4 2025.
- A 5-year average of $208823.5 and a median of $159000.0 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation jumped 213.66% in 2022, then tumbled 65.87% in 2025.
- Over 5 years, Share-based Compensation stood at $159000.0 in 2022, then slipped by 0.63% to $158000.0 in 2023, then slumped by 46.2% to $85000.0 in 2024, then slumped by 34.12% to $56000.0 in 2025, then jumped by 50.0% to $84000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $84000.0, $56000.0, and $86000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | - |
| 10 | Cocrystal Pharma | 16.13 Mn | 13.81 Mn | - | 426,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 426,000.00 |
| Jun 30, 2026 | 426,000.00 |
| Mar 31, 2026 | 84,000.00 |
| Mar 31, 2026 | 84,000.00 |
| Dec 31, 2025 | 56,000.00 |
| Dec 31, 2025 | 56,000.00 |
| Sep 30, 2025 | 86,000.00 |
| Sep 30, 2025 | 86,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Sep 30, 2024 | 252,000.00 |
| Jun 30, 2024 | 166,000.00 |
| Jun 30, 2024 | 166,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Mar 31, 2024 | 157,000.00 |